Quote:
Originally Posted by missj
from delawareonline I found this
The data’s implications may be limited because the study was designed to show a 40 percent risk reduction with interferon treatment, more than the 30 percent shown in trials of the interferon beta therapies or Copaxone, Kappos and Tobias Derfuss, also of University Hospital in Basel, wrote in their editorial.
hmmmm
|
Supposedly the design of the trial was done very well. While we often hear stats from the drug companies stating "reduction in risk", the bottom line in this trial was to compare disease progression level between those who used interferon beta and those who used nothing. And it was here they found no difference!!
But if you read the literature of the companies who produce this drug, you would get a totally different outlook. Ah the importance of marketing and how it can influence people to use something even though it may not give you what was inferred. The CRAB drug producers have been doing this for years and making a ton of money along the way. Too bad most MS patients haven't benefited much if at all.